Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.

Author: CzendlikC H, HowaldH, PreiswerkG, SioufiA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigates the interaction between valsartan (V), an angiotensin II receptor blocker, and atenolol (A), a beta-adrenoceptor blocker, when co-administered for hypertension treatment. The findings suggest that both drugs affect the pharmacokinetics of each other, but the combination does not significantly alter the pharmacodynamic effects on blood pressure, heart rate, or renin activity.
Paper Details　
Original Abstract of the Article :
Valsartan (V), a specific inhibitor of the angiotensin II receptor subtype, AT1, has been developed for treatment of hypertension. Combination therapy with a beta-adrenoceptor blocking agent might be considered in cases with insufficient efficacy of V alone. Therefore, an interaction trial was perfo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s002280050318

データ提供：米国国立医学図書館（NLM）

Valsartan and Atenolol: A Duo Navigating the High Road to Lower Blood Pressure

High blood pressure is a prevalent condition, often requiring a combination of medications to achieve optimal control. This study examines the interaction between valsartan, a specific inhibitor of angiotensin II receptor, and atenolol, a beta-adrenoceptor blocker. The researchers investigated whether co-administering these drugs would affect their pharmacokinetics and pharmacodynamics, essentially looking at how each drug influenced the other's absorption, distribution, metabolism, and excretion, as well as their effects on blood pressure and heart rate. The findings suggest that valsartan and atenolol can be safely used together, with each drug maintaining its intended effect without significant interference from the other.

A Balanced Ecosystem: The Harmony of Valsartan and Atenolol

This study demonstrates that the combination of valsartan and atenolol works like a well-balanced ecosystem, where each component plays its role without disrupting the others. This means that the drugs can effectively lower blood pressure without compromising their individual mechanisms of action. This finding could be beneficial for patients who require a combination therapy to control their blood pressure.

A Desert Oasis of Blood Pressure Management: What Does This Mean for You?

This research offers a ray of hope for individuals struggling with high blood pressure who require multiple medications. It suggests that valsartan and atenolol can be safely and effectively combined to achieve optimal blood pressure control. However, it is crucial to consult with your healthcare provider to determine the most appropriate treatment plan based on your individual needs and medical history.

Dr. Camel's Conclusion

In the vast desert of hypertension treatment, finding the right combination of medications is like finding a hidden spring. This study shows that valsartan and atenolol can work together harmoniously, offering a refreshing oasis for patients seeking effective blood pressure control.

Date :
  1. Date Completed 1997-11-20
  2. Date Revised 2019-08-13
Further Info :

Pubmed ID

9342580

DOI: Digital Object Identifier

10.1007/s002280050318

Related Literature

Article Analysis
・Effects of valsartan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.